Shionogi Completes Acquisition of Japan Tobacco's Pharmaceutical Business and Plans Manufacturing Subsidiary Merger
核心洞察
Shionogi (搜索) has completed the succession of Japan Tobacco Inc.'s pharmaceutical business and acquisition of Akros Pharma Inc. shares through a simplified absorption-type company split.
The Japanese pharmaceutical company announced plans to merge with its wholly owned manufacturing subsidiary Shionogi Pharma Co., Ltd., effective April 1, 2027.
The merger aims to strengthen functional collaborations and build a robust production and supply system to adapt to environmental changes in the pharmaceutical supply chain.
Shionogi (搜索) & Co., Ltd. announced on December 1, 2025, the completion of its acquisition of Japan Tobacco Inc.'s pharmaceutical business through a simplified absorption-type company split, along with the acquisition of shares of Akros Pharma Inc. by Shionogi Inc. The transaction, originally announced in May 2025, represents a significant expansion of Shionogi's pharmaceutical portfolio and capabilities.
Strategic Manufacturing Integration
In a separate but related development, Shionogi (搜索) revealed plans for an absorption-type merger with its wholly owned manufacturing subsidiary, Shionogi Pharma Co., Ltd., scheduled for April 1, 2027. The Board of Directors approved this merger on October 27, 2025, as part of the company's broader transformation strategy.
Shionogi (搜索) Pharma serves as the company's manufacturing subsidiary responsible for producing prescription pharmaceuticals and investigational new drugs. The merger is designed to integrate production, pharmaceutical technology development, sales and marketing functions to create a more flexible and resilient supply system.
Addressing Supply Chain Challenges
According to Shionogi (搜索), the pharmaceutical supply chain environment has undergone significant changes, including increased geopolitical risks and stricter quality regulations, making global supply chain management increasingly challenging. The company emphasized that demand for infectious disease (搜索) drugs can fluctuate significantly depending on outbreak situations, requiring flexible responses to ensure stable medication supply to patients and healthcare providers.
"It is essential to integrate and collaborate across production, pharmaceutical technology development, sales and marketing, and other functions to build a flexible and resilient production and supply system," the company stated in its announcement.
Transformation Strategy Implementation
These moves align with Shionogi (搜索)'s Medium-term Business Plan, SHIONOGI Transformation Strategy 2030 Revision, which focuses on accelerating globalization and business expansion. The strategy primarily centers on the company's in-house discovered infectious disease (搜索) products, positioning Shionogi to better compete in the global pharmaceutical market.
The merger with Shionogi (搜索) Pharma will be structured as a simplified absorption-type merger, with Shionogi as the surviving company. Since Shionogi Pharma is a wholly owned subsidiary, no new shares will be issued, and no cash or other consideration will be allocated in the transaction.
Timeline and Regulatory Process
The merger process follows a structured timeline, with the memorandum of understanding planned for November 2025, followed by the merger agreement signing in February 2027. The transaction qualifies as a simplified absorption-type split under Article 796, Paragraph 2 of the Companies Act and a short form merger under Article 784, Paragraph 1, allowing approval without a shareholders' meeting resolution.